Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lepu Biopharma Co's total inventories for the quarter that ended in Dec. 2025 was HK$57 Mil. Lepu Biopharma Co's average total inventories from the quarter that ended in Jun. 2025 to the quarter that ended in Dec. 2025 was HK$54 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Lepu Biopharma Co's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was HK$-0.42.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Lepu Biopharma Co's Days Inventory for the
six
months ended in Dec. 2025 was 144.01.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Lepu Biopharma Co's Inventory Turnover for the quarter that ended in Dec. 2025 was 1.27.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Lepu Biopharma Co's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 0.10.
Lepu Biopharma Co (HKSE:02157) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Lepu Biopharma Co's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Lepu Biopharma Co's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Lepu Biopharma Co Total Inventories Related Terms
Lepu Biopharma Co Total Inventories Historical Data
* Premium members only.
The historical data trend for Lepu Biopharma Co's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Lepu Biopharma Co (HKSE:02157) has a Total Inventories of HK$57 Mil as of Dec. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for Lepu Biopharma Co and its competitors.
Is Lepu Biopharma Co's Total Inventories too high?
Lepu Biopharma Co's current Total Inventories is HK$57 Mil. Overall, Lepu Biopharma Co has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lepu Biopharma Co's Total Inventories compare to VRTX and REGN?
Lepu Biopharma Co's Total Inventories of HK$57 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Lepu Biopharma Co and its competitors. Lepu Biopharma Co's current Total Inventories is HK$57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lepu Biopharma Co stock overvalued right now?
Based on GuruFocus' analysis, Lepu Biopharma Co (HKSE:02157) is currently considered Possible Value Trap. The stock's GF Value™ is HK$15.69, compared to a current price of HK$4.65 — trading 70.4% below its estimated fair value. The current Total Inventories is HK$57 Mil. Lepu Biopharma Co's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Lepu Biopharma Co (HKSE:02157), the current Total Inventories is HK$57 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lepu Biopharma Co (HKSE:02157) Overvalued in 2026?
Based on GuruFocus' analysis, Lepu Biopharma Co stock appears to be undervalued.
The current stock price of HK$4.65 is trading 70.4% below its estimated GF Value™ of HK$15.69.
GuruFocus considers Lepu Biopharma Co to be Possible Value Trap.
Key valuation signals for HKSE:02157:
Total Inventories: HK$57 Mil
GF Value™: HK$15.69 vs. price of HK$4.65 (70.4% below fair value)
No single metric tells the full story. See the HKSE:02157 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lepu Biopharma Co Ltd is focused on discovering, developing, and commercializing drug candidates in anti-tumor targeted therapy and oncology immunotherapy. Its commercial products include Puyouheng (Pucotenlimab Injection) and Meiyouheng (Becotatug Vedotin Injection). In addition, two other products, CMG901 and MRG007, have also been licensed out through its business development activities. Additionally, the company has several clinical-stage drug candidates and clinical-stage combination therapies of candidates, which are being developed as targeted therapeutics and immunotherapeutics. The various drug candidates in its pipeline include MRG003, MRG002, MRG004A, CG0070, MRG001, and MRG006A, among others. Geographically, the company generates maximum revenue from the Chinese mainland.
44GF Score
Get the complete analysis for HKSE:02157
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02157 has been successfully added to your 
